{"id":497551,"date":"2024-01-26T19:30:15","date_gmt":"2024-01-27T00:30:15","guid":{"rendered":"https:\/\/platohealth.ai\/public-equity-roundup-cg-arrivent-ipos-stoke-optimism-for-growing-queue\/"},"modified":"2024-01-27T07:17:04","modified_gmt":"2024-01-27T12:17:04","slug":"public-equity-roundup-cg-arrivent-ipos-stoke-optimism-for-growing-queue","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/public-equity-roundup-cg-arrivent-ipos-stoke-optimism-for-growing-queue\/","title":{"rendered":"Public equity roundup: CG, ArriVent IPOs stoke optimism for growing queue","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

ARTICLE | Finance<\/p>\n

\n
\n
\n

Plus: Follow-ons for Sagimet, Tourmaline and Adicet, and PIPEs for Kura, ORIC and CalciMedica<\/h2>\n

\n By Paul Bonanos, Director of Biopharma Intelligence<\/span>\n<\/p>\n

January 27, 2024 12:30 AM UTC<\/p>\n<\/div>\n<\/div>\n<\/div>\n

<\/span><\/span><\/div>\n

New listings from CG Oncology and ArriVent provided hopeful signs for a 2024 rebound in the biotech IPO market, while cash continued to flow into biopharmas via follow-ons and PIPEs.<\/p>\n

Enthusiasm for the listing by CG Oncology Inc.<\/a><\/b> (NASDAQ:CGON) gained momentum during the week, as the company first upsized its proposal, then priced above expectations and gained value in the aftermarket. An initial 11.8 million-share proposal swelled to 17 million shares; CG then sold 20 million shares at the top of its range, raising $380 million \u2014 the most for a new-to-NASDAQ biotech since the $621 million offering by Acelyrin Inc. in May 2023…<\/p>\n